Gilead Sciences

Principle Medical Key Account Lead - Southeast

United States

Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

The Principal Medical Key Account Lead must have experience in leading medical interfaces with key health systems, academic medical centers, GPOs, and Pathway accounts, focusing on HIV and oncology. This role requires the ability to develop sustainable customer relationships and communicate clinical, scientific, health economic, and outcomes research data, including real-world evidence and patient-reported outcomes. The position also necessitates developing and executing strategic medical plans and tactics for assigned accounts, generating real-world evidence data, and collaborating with internal teams such as Commercial Oncology Key Account Directors, HIV Institutional Account Directors, Therapeutic Area Medical Science Liaisons, Clinical Development, Clinic Operations, and home office medical matrix teams. A strong understanding of patient access, the evolving healthcare environment, and customer needs is essential.

Responsibilities

The Principal Medical Key Account Lead will be responsible for developing and maintaining access to key account stakeholders to facilitate scientific interchange for Gilead's HIV and oncology innovations, with a priority on launch products. They will develop strategic medical plans and tactics for their accounts, implement customer-specific Real-World Evidence (RWE) data generation, and work with PAQ strategy teams to interpret and disseminate data assessing the medical value of Gilead's portfolio. This role involves managing approximately 10-15 critical key accounts, primarily the largest US academic health and key health systems, and collaborating with commercial and medical affairs colleagues. The lead will provide strong leadership in developing account-specific medical strategies related to patient access and the healthcare environment. Additionally, they will effectively communicate approved clinical, scientific, and outcomes data, and accurately respond to customer questions during scientific exchanges with various stakeholders, including access and policy decision-makers, department heads, executive medical and institutional stakeholders, scientific advisors, and healthcare policymakers.

Skills

HIV
Oncology
Health Systems
Academic Medical Centers
GPOs
Customer Relationship Management
Clinical Communication

Gilead Sciences

Develops and commercializes biopharmaceuticals

About Gilead Sciences

Gilead Sciences focuses on discovering, developing, and commercializing medicines for various medical conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company conducts extensive research and development to create new therapies, which are then marketed to healthcare providers, hospitals, and pharmacies after receiving regulatory approval. Gilead differentiates itself from competitors through its strong commitment to R&D and strategic partnerships, such as with SAP Ariba, to enhance its operations and product offerings. The company's goal is to improve health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Foster City, CaliforniaHeadquarters
1987Year Founded
$15,873.6MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Benefits

Paid family time off and paid parental time off
Generous 401(k) contribution matching
Comprehensive medical plans that cover both physical and mental healthcare
Global Wellbeing Reimbursement
Time Off
Global Volunteer Day
Giving Together Program
Employee Support Programs
Flexible Work Options

Risks

Increased competition in HIV treatment from ViiV Healthcare's expanding drug portfolio.
Regulatory scrutiny over drug pricing could impact Gilead's U.S. market operations.
Patent expirations, like Truvada's, lead to increased generic competition and revenue loss.

Differentiation

Gilead's lenacapavir is recognized as the 2024 Breakthrough of the Year for HIV care.
Partnerships with LEO Pharma and Tubulis enhance Gilead's focus on inflammatory and cancer therapies.
Gilead's commitment to health equity initiatives like COMPASS and HepConnect sets it apart.

Upsides

Gilead's strategic partnerships expand its reach in inflammatory and oncology drug markets.
Investment in digital health technologies enhances Gilead's R&D and patient engagement.
Focus on sustainability improves Gilead's operational efficiency and corporate reputation.

Land your dream remote job 3x faster with AI